Phaseline

Companies › Laboratoires Thea

Laboratoires Thea: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Ophthalmology, Immunology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sepofarsen (QR-110)
CEP290 mRNA positive modulator
CEP290Phase 3Leber Congenital Amaurosis 10Nov 2027
T1695–Phase 2Moderate to Severe Vernal KeratoconjunctivitisJan 2027
T10430–Phase 2MyopiaNov 2027
Ultevursen
USH2A exon 13 gene therapy
USH2APhase 2Retinitis Pigmentosa (RP)Jul 2028
T4090
Kinezodianone R hydrochloride
–Phase 1Glaucoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05389267T4090Phase 1GlaucomaOphthalmologyDec 2024
NCT07169695T1695Phase 2Moderate to Severe Vernal KeratoconjunctivitisImmunologyJan 2027
NCT06891443Sepofarsen (QR-110)Phase 3Leber Congenital Amaurosis 10OphthalmologyNov 2027
NCT07522242T10430Phase 2MyopiaOphthalmologyNov 2027
NCT06627179UltevursenPhase 2Retinitis Pigmentosa (RP)OphthalmologyJul 2028

Targets

CEP290 (1) USH2A (1)

Companies with the same targets

ProQR Therapeutics Ocugen

Companies built like this

Ocugen ProQR Therapeutics Huons Vantage Biosciences Sunhawk Vision Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.